GAS5 and prostate cancer: Luo et al. demonstrated that GAS5 enhances the promoter activity of cyclin-dependent kinase inhibitor 1B (P27Kip1), a regulator of cell cycle, by enhancing the binding of E2F1 to P27Kip1 promotor in prostate cancer (10).